Fernanda Damian
A5091843646- Cervical Cancer and HPV Research
- Cancer Immunotherapy and Biomarkers
- Endometrial and Cervical Cancer Treatments
- Global Cancer Incidence and Screening
- Women's cancer prevention and management
- Advanced Breast Cancer Therapies
- Immunotherapy and Immune Responses
- Ovarian cancer diagnosis and treatment
- Occupational Health and Burnout
- Cancer Mechanisms and Therapy
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Healthcare Systems and Public Health
- Erythropoietin and Anemia Treatment
- Ultrasound in Clinical Applications
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Healthcare during COVID-19 Pandemic
- Education during COVID-19 pandemic
- Bladder and Urothelial Cancer Treatments
- Virus-based gene therapy research
- Orthodontics and Dentofacial Orthopedics
- Endometriosis Research and Treatment
- Tuberous Sclerosis Complex Research
Hospital São Lucas da PUCRS
2018-2025
Pontifícia Universidade Católica do Rio Grande do Sul
2022-2025
Centro de Pesquisas Oncológicas
2018-2025
Instituto de Pesquisas Jardim Botânico do Rio de Janeiro
2023
Grupo Hospitalar Conceição
2023
Universidade Federal do Rio Grande do Sul
2004-2022
Memorial Hospital
2022
Pontifícia Universidade Católica de São Paulo
2022
Eastern Cooperative Oncology Group
2022
Universidad de Santiago de Chile
2022
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)–blocking antibody approved to treat lung and skin cancers, has been shown preliminary clinical activity in this population.
PURPOSE Despite marked advances in the treatment of unresectable or metastatic melanoma, need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy phase II PIVOT-02 trial. PIVOT IO 001 (ClinicalTrials.gov identifier: NCT03635983 ) is III, randomized, open-label study that builds on results first-line melanoma. METHODS Patients with previously untreated, unresectable, melanoma were randomly assigned 1:1 to receive...
PURPOSE Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) the phase III Study 309/KEYNOTE-775. We report results from III, randomized, open-label European Network of Gynaecological Oncological Trial-en9/LEAP-001 study (ClinicalTrials.gov identifier: NCT03884101 ) that evaluated len pembro first-line aEC. METHODS Patients with stage to IV...
5522 Background: Cemiplimab + ISA101b vaccine is being studied in HPV16-positive cancers several phase 2 clinical trials. Here, we present the efficacy and safety results of a study cemiplimab patients with recurrent HPV16 cervical cancer who had disease progression after first-line chemotherapy (NCT04646005). Methods: Patients received 350 mg administered intravenously every 3 weeks doses 100 µg/peptide by subcutaneous injection on Days 1, 29, 50. The primary endpoint was objective response...
To assess the impact of hydronephrosis and kidney function in newly diagnosed advanced cervical cancer patients.A retrospective cohort study stage IIIB to IVB was conducted a tertiary hospital Brazil. Data from clinical records between 2014 2018 were reviewed.A total 285 women with no previous treatment included. 108 (37.9%) patients (HN) before or during first treatment, 49 (17.2%) underwent ureteral obstruction relief, emergency hemodialysis performed 17 due uremia. The median overall...
Cervical cancer is the fourth most common in women worldwide. Epidemiological and quality of life (QoL) data patients with cervical from low- middle-income countries are scarce. We aimed to describe sociodemographic clinicopathological characteristics at diagnosis Brazil.EVITA a prospective cohort study newly diagnosed May 2016 December 2017, stages I-IVB, 16 Brazilian sites representing five regions. At baseline, medical evaluation was performed European Organization for Research Treatment...
Palbociclib is a cyclin-dependent kinase 4/6 inhibitor that approved in the United States for treatment of hormone receptor‒positive (HR+)/human epidermal growth factor receptor‒2 negative (HER2−) advanced breast cancer (ABC). The objectives this expanded access trial were to provide palbociclib combination with letrozole patients HR+/HER2− ABC Argentina, Brazil, Colombia, and Mexico who candidates therapy before commercial availability palbociclib, evaluate safety tolerability plus...
(Abstracted from N Engl J Med 2022;386(6):544–555) Despite widespread implementation of cervical cancer screening and prevention programs including cytologic assessment high-risk human papillomavirus DNA detection as well effective vaccines, the incidence remains high. Treatment varies based on stage grade involves a combination surgery, platinum-based chemotherapy, bevacizumab, chemoradiation, intracavitary brachytherapy.
<h3>Objectives</h3> EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 is an open-label, randomized (1:1), multi-center, Phase 3 trial of cemiplimab vs investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical cancer that has progressed after first-line (1L) platinum-based treatment (tx). <h3>Methods</h3> Patients (pts) were enrolled regardless PD-L1 expression; received 350 mg IV Q3W or IC chemo (pemetrexed, vinorelbine, gemcitabine, irinotecan, topotecan), up to 96 weeks;...
5514 Background: Treatment options for patients with high-grade ovarian serous (HGSC) or endometrioid carcinoma (HGEC) who progress after receiving chemotherapy recurrence are limited. Methods: LACOG 1018, a phase II, single-arm, multicenter trial evaluated the efficacy of letrozole 2.5mg/day po continuously plus palbociclib 125mg/day 21 days in 28-day cycles histologically proven HGSC HGEC, fallopian tube peritoneal cancer had progressed on prior locoregional metastatic disease (at least...
Abstract Background: Breast cancer (BC) is the most common malignancy and one of leading causes death in women Latin America (LATAM). Studies have highlighted importance understanding contextual characteristics each patient population to inform health policy-making. However, few data are available on from LATAM, a region with marked inequalities. Methods: LATINA (LACOG 0615/MO39485) multicenter prospective cohort study designed describe sociodemographic characteristics, diagnosis, treatment,...
Abstract Background: Breast cancer (BC) is the most common malignancy and one of leading causes death in women Latin America (LATAM). However, region lacks a unified multinational initiative to investigate BC further understand regional disparities. Methods: LATINA (LACOG 0615/MO39485) first prospective cohort study designed describe clinicopathological characteristics, treatment patterns, outcomes patients with LATAM. Patients aged ≥18 years diagnosed primary or recurrent 12 months...
e17510 Background: Cervical cancer (CC) is the fourth most common malignancy in women worldwide and around 85% of cases are currently diagnosed underdeveloped countries. Effective screening with Pap smear HPV test can reduce incidence CC about 90%. In Brazil, few retrospective/cancer registry studies have described patterns previous to diagnosis. We aim assess rates major study Brazil (EVITA). Methods: Prospective, observational study, within 16 sites representing five Brazilian regions....
e17509 Background: Cervical cancer (CC) is the fourth most common malignancy in women worldwide and third Brazil. It a health problem low middle-income countries (LMIC), where screening programs have failed to achieve its potential 85% of global disease burden is. Therefore, studies aiming describe population patients those are uttermost importance for planning public policies. EVITA major prospective CC cohort study performed Here we present patients’ baseline characteristics diagnostics...